RxDoctor Payments Data

Charles Dodgen, MD

Family Medicine · Thomaston, GANPI 1104846625

Payments from drug & device makers

$994in general payments, 2019–2025

Across 28 payments — averaging $35.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$498
  • Otsuka America Pharmaceutical, Inc.$222
  • Pfizer$69
  • Novo Nordisk$59
  • GSK$54
  • Amgen$35
  • plus $59 from 3 others

What the payments were for

  • Food & beverage$994100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)7$498
Otsuka America Pharmaceutical, Inc.10$222
Pfizer3$69
Novo Nordisk2$59
GSK1$54
Amgen2$35
Lilly USA, LLC1$23
Bayer1$22
Dexcom, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$994 in reported general payments places this provider in the 55th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$135,247
Medicare patients
158
Services billed
3,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$88,543
EnbrelEtanercept12$87,916
XareltoRivaroxaban27$18,120
OzempicSemaglutide18$17,129
FarxigaDapagliflozin Propanediol15$16,821
NamzaricMemantine Hcl/Donepezil Hcl19$13,276
JardianceEmpagliflozin13$12,732
MyrbetriqMirabegron38$12,480
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen329$7,526
Hydroxychloroquine Sulfate179$6,717
Fluvoxamine Maleate135$3,091
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$2,940
Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide108$2,811
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen51$2,314
Omeprazole162$2,300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$69$88,54395 claims
AmgenEnbrel$35$87,91612 claims
Novo NordiskOzempic$59$17,12918 claims
AbbVieNamzaric$498$13,27619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Thomaston

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →